Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John Vose is active.

Publication


Featured researches published by John Vose.


Molecular Immunology | 1991

A novel process for preparing an acellular pertussis vaccine composed of non-pyrogenic toxoids of pertussis toxin and filamentous hemagglutinin.

Larry U. L. Tan; Raafat Fahim; Gail Jackson; Kimberly M. Phillips; Po Wah; Dirk Alkema; Gloria Zobrist; Andrew P. Herbert; Leslie Boux; Pele Chong; Nadir Harjee; Michel Klein; John Vose

A novel process for preparing non-pyrogenic toxoids of pertussis toxin (PT) and filamentous hemagglutinin (FHA) is described. The process consists of chromatographies on perlite then on hydroxylapatite. Purification yields for PT and FHA are 62 and 68%, respectively. The purification process takes advantage of the novel use of perlite (a filter aid) for the simultaneous purification of PT and FHA. The hydroxylapatite, in addition to removing the remaining contaminants, also concentrates the antigens. The resulting PT and FHA are approximately 95% pure, and are non-pyrogenic as judged by the rabbit pyrogen test. The purification process is simple, inexpensive, and does not use blood components or toxic substances. The mild conditions in which the PT and FHA are purified ensure the recovery of native protein. The purified PT and FHA are detoxified in the presence of glycerol using glutaraldehyde and formaldehyde, respectively, to produce antigenic components of an acellular pertussis vaccine. The final PT and FHA toxoids are immunogenic in guinea-pigs and have been shown to be protective in the mouse intracerebral challenge test.


Clinical Infectious Diseases | 2001

Perspectives on the manufacture of combination vaccines.

John Vose

Evolving regulatory requirements in the United States and Europe create major challenges for manufacturers tasked with production of vaccines that contain > or =9 separate antigens capable of protecting against infectious diseases, such as diphtheria, tetanus, pertussis, polio, hepatitis B, and Haemophilus influenza b, in a single shot. This article describes 10 steps that can facilitate the process of licensing these complex vaccines. It also points out problems associated with the use of animal tests for the crucial step of potency testing for batch release caused by the inherent variability of such tests and the difficulties of interpreting their results.


Biofutur | 1997

Vaccine containing Bordetella pertussis outer membrane protein, and method of making such vaccine

Gail Jackson; Raafat Fahim; Larry U. L. Tan; Pele Chong; John Vose; M. Klein

A component vaccine against disease caused by infection by Bordetella pertussis, characterized by: as a first component, purified pertactin having no detectable adenylate cyclase activity, as at least one additional component thereof, at least one other purified B. pertussis antigen which is pertussis toxin (PT), filamentous haemagglutinin (FHA) and/or agglutinogens; as at least two further components thereof, at least two other purified non-Bordetella antigens which are diphtheria toxoid (D) and tetanus toxoid (T); and a pharmaceutically-acceptable carrier therefor.


Archive | 1996

Acellular pertussis vaccines and methods of preparation thereof

John Vose; Raafat E. F. Fahim; Gail E. D. Jackson; Larry U. L. Tan; Andrew Herbert; Leslie Boux; Luis Barreto; John Thipphawong; M. Klein


Archive | 1991

Purification of a pertussis outer membrane protein

Gail Jackson; Raafat Fahim; Larry U. L. Tan; Pele Chong; John Vose; Michel H. Klein


Archive | 1991

Purification and use of pertactin, a bordetella pertussis outer membrane protein

Gail Jackson; Raafat Fahim; Larry U. L. Tan; Pele Chong; John Vose; Michel H. Klein


Archive | 1996

Acellulære pertussisvacciner og fremgangsmåder til fremstilling heraf

John Vose; Gail Jackson; Larry U. L. Tan; Andrew P. Herbert; Leslie Boux; Luis Barreto; John Thipphawong; M. Klein; Raafat Fahim


Archive | 1996

Vaccines and acellular pertussis procedures for preparation thereof.

Luis Barreto; Leslie Boux; Raafat Fahim; Andrew P. Herbert; Gail Jackson; M. Klein; Larry U. L. Tan; John Thipphawong; John Vose


Archive | 1996

Methods of preparation of components of acellular pertussis vaccines

Raafat E. F. Fahim; John Vose; John Thipphawong; Luis Barreto; Gail E. D. Jackson; Andrew Herbert; Michel H. Klein


Archive | 1996

Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants

Luis Barreto; Leslie Boux; Raafat Fahim; Andrew P. Herbert; Gail Jackson; Michel H. Klein; Larry U. L. Tan; John Thipphawong; John Vose

Collaboration


Dive into the John Vose's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gail Jackson

National Research Council

View shared research outputs
Top Co-Authors

Avatar

Raafat Fahim

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pele Chong

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge